Arcutis Biotherapeutics, Inc. ARQT Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
- Arcutis Biotherapeutics, Inc. (ARQT) reported share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value of $90.57M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value increased by 74.1% year-over-year, from $52.02M to $90.57M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, intrinsic value has grown at a 16.6% compound annual growth rate (CAGR), from $59.27M to $127.95M.